1. WHO (2010) Global leprosy situation, 2010. Wkly Epidemiol Rec 85: 337–348.
2. BrittonWJ, LockwoodDN (2004) Leprosy. Lancet 363: 1209–1219.
3. ScollardDM, AdamsLB, GillisTP, KrahenbuhlJL, TrumanRW, et al. (2006) The continuing challenges of leprosy. Clin Microbiol Rev 19: 338–381.
4. RidleyDS, JoplingWH (1966) Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255–273.
5. FavaV, OrlovaM, CobatA, AlcaisA, MiraM, et al. (2012) Genetics of leprosy reactions: an overview. Mem Inst Oswaldo Cruz 107 ((Suppl. I)) 132–42.
6. WalkerSL, LockwoodDN (2007) Leprosy. Clin Dermatol 25: 165–172.
7. KumarB, DograS, KaurI (2004) Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 72: 125–133.
8. RanqueB, NguyenVT, VuHT, NguyenTH, NguyenNB, et al. (2007) Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44: 33–40.
9. LittleD, Khanolkar-YoungS, CoulthartA, SuneethaS, LockwoodDN (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 3413–3417.
10. RoseP, WatersMF (1991) Reversal reactions in leprosy and their management. Lepr Rev 62: 113–121.
11. VerhagenCE, WierengaEA, BuffingAA, ChandMA, FaberWR, et al. (1997) Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol 159: 4474–4483.
12. StefaniMM, MartelliCM, GillisTP, KrahenbuhlJL (2003) In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188: 1024–1031.
13. MoraesMO, SarnoEN, AlmeidaAS, SaraivaBC, NeryJA, et al. (1999) Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol 50: 541–549.
14. MoraesMO, SampaioEP, NeryJA, SaraivaBC, AlvarengaFB, et al. (2001) Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient. Br J Dermatol 144: 175–181.
15. Khanolkar-YoungS, RaymentN, BrickellPM, KatzDR, VinayakumarS, et al. (1995) Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99: 196–202.
16. Becx-BleuminkM, BerheD (1992) Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 60: 173–184.
17. van BrakelWH, KhawasIB, LucasSB (1994) Reactions in leprosy: an epidemiological study of 386 patients in west Nepal. Lepr Rev 65: 190–203.
18. SchreuderPA (1998) The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995 [correction of 1978–1995]. II. Reactions. Int J Lepr Other Mycobact Dis 66: 159–169.
19. SharmaN, KoranneRV, MendirattaV, SharmaRC (2004) A study of leprosy reactions in a tertiary hospital in Delhi. J Dermatol 31: 898–903.
20. HuangdW, ShermanBT, LempickiRA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44–57.
21. DennisGJr, ShermanBT, HosackDA, YangJ, GaoW, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: R60.1–R60.11.
22. AshburnerM, BallCA, BlakeJA, BotsteinD, ButlerH, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.
23. LeeHK, BraynenW, KeshavK, PavlidisP (2005) ErmineJ: tool for functional analysis of gene expression data sets. BMC Bioinformatics 6: 269–276.
24. GillisJ, MistryM, PavlidisP (2010) Gene function analysis in complex data sets using ErmineJ. Nat Protoc 5: 1148–1159.
25. BrittonWJ (1998) The management of leprosy reversal reactions. Lepr Rev 69: 225–234.
26. WalkerSL, LockwoodDN (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372–386.
27. CooperCL, MuellerC, SinchaisriTA, PirmezC, ChanJ, et al. (1989) Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 169: 1565–1581.
28. KirkaldyAA, MusondaAC, Khanolkhar-YoungS, SuneethaS, LockwoodDN (2003) Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol 134: 447–453.
29. PesceC, GrattarolaM, MeniniS, FialloP (2006) Cyclooxygenase 2 expression in vessels and nerves in reversal reaction leprosy. Am J Trop Med Hyg 74: 1076–1077.
30. MindrescuC, LeJ, WisniewskiHG, VilcekJ (2005) Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun 330: 737–745.
31. KozakKR, RowlinsonSW, MarnettLJ (2000) Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 275: 33744–33749.
32. FournierT, MedjoubiN, PorquetD (2000) Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482: 157–171.
33. GuptaN, ShankernarayanNP, DharmalingamK (2010) alpha1-acid glycoprotein as a putative biomarker for monitoring the development of the type II reactional stage of leprosy. J Med Microbiol 59: 400–407.
34. KupcovaV, TureckyL, DetkovaZ, PrikazskaM, KeleovaA (2003) Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiol Res 52: 89–93.
35. SallenaveJM (2000) The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease. Respir Res 1: 87–92.
36. HenriksenPA, HittM, XingZ, WangJ, HaslettC, et al. (2004) Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immunol 172: 4535–4544.
37. ThomasSR, StockerR (1999) Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 4: 199–220.
38. BelladonnaML, GrohmannU, GuidettiP, VolpiC, BianchiR, et al. (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177: 130–137.
39. KostopanagiotouG, AvgerinosE, CostopanagiotouC, ArkadopoulosN, AndreadouI, et al. (2008) Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time depended role of phospholipases A(2). J Surg Res 147: 108–116.
40. FrancoR, PachecoR, GatellJM, GallartT, LluisC (2007) Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 27: 495–509.
41. FischerJ, WestJ, AgochukwuN, SuireC, Hale-DonzeH (2007) Induction of host chemotactic response by Encephalitozoon spp. Infect Immun 75: 1619–1625.
42. CastellinoF, HuangAY, Altan-BonnetG, StollS, ScheineckerC, et al. (2006) Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440: 890–895.
43. McKinneyC, MerrimanME, ChapmanPT, GowPJ, HarrisonAA, et al. (2008) Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann Rheum Dis 67: 409–413.
44. BertiniR, LuiniW, SozzaniS, BottazziB, RuggieroP, et al. (1995) Identification of MIP-1 alpha/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. AIDS Res Hum Retroviruses 11: 155–160.
45. ZlotnikA, YoshieO (2000) Chemokines: a new classification system and their role in immunity. Immunity 12: 121–127.
46. RamadasRA, EwartSL, MedoffBD, LevineAM (2011) Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs. Am J Respir Cell Mol Biol 44: 134–145.
47. CavaillonJM (1994) Cytokines and macrophages. Biomed Pharmacother 48: 445–453.
48. AtzeniF, Sarzi-PuttiniP (2009) Anti-cytokine antibodies for rheumatic diseases. Curr Opin Investig Drugs 10: 1204–1211.
49. MookherjeeN, BrownKL, BowdishDM, DoriaS, FalsafiR, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455–2464.
50. SabanR, D'AndreaMR, Andrade-GordonP, DerianCK, DozmorovI, et al. (2007) Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol 7: 3–17.
51. ChenLC, ChenCC, LiangY, TsangNM, ChangYS, et al. (2011) A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Mod Pathol 24: 175–184.
52. LiuH, ChenA, GuoF, YuanL (2010) A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 295: 27–37.
53. RobertsonBW, BonsalL, ChellaiahMA (2010) Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 9: 260–269.
54. DelimpouraV, BakakosP, TseliouE, BessaV, HillasG, et al. (2010) Increased levels of osteopontin in sputum supernatant in severe refractory asthma. Thorax 65: 782–786.
55. NauGJ, ChuppGL, EmileJF, JouanguyE, BermanJS, et al. (2000) Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Pathol 157: 37–42.
56. ChangIF, HsiaoHY (2005) Induction of RhoGAP and pathological changes characteristic of Alzheimer's disease by UAHFEMF discharge in rat brain. Curr Alzheimer Res 2: 559–569.
57. FestenEA, GoyetteP, GreenT, BoucherG, BeauchampC, et al. (2011) A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. PLoS Genet 7: e1001283.
58. EyreS, HinksA, BowesJ, FlynnE, MartinP, et al. (2010) Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther 12: R175–R180.
59. MonteiroRC, Van De WinkelJG (2003) IgA Fc receptors. Annu Rev Immunol 21: 177–204.
60. KnowlesHJ, te PoeleRH, WorkmanP, HarrisAL (2006) Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71: 646–656.
61. ChoudharyD, JanssonI, StoilovI, SarfaraziM, SchenkmanJB (2004) Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos 32: 840–847.
62. BirnbaumerM (2000) Vasopressin receptors. Trends Endocrinol Metab 11: 406–410.
63. WangXJ, DysonMT, MondilloC, PatrignaniZ, PignataroO, et al. (2002) Interaction between arachidonic acid and cAMP signaling pathways enhances steroidogenesis and StAR gene expression in MA-10 Leydig tumor cells. Mol Cell Endocrinol 188: 55–63.
64. WilliamsJP, WeiserMR, PechetTT, KobzikL, MooreFDJr, et al. (1997) alpha 1-Acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat. Am J Physiol 273: G1031–G1035.
65. SallenaveJM, CunninghamGA, JamesRM, McLachlanG, HaslettC (2003) Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect Immun 71: 3766–3774.
66. MoilanenM, SorsaT, StenmanM, NybergP, LindyO, et al. (2003) Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 42: 5414–5420.
67. KosakaT, YoshinoJ, InuiK, WakabayashiT, KobayashiT, et al. (2009) Involvement of NAD(P)H:quinone oxidoreductase 1 and superoxide dismutase polymorphisms in ulcerative colitis. DNA Cell Biol 28: 625–631.
68. GaoB, FloresSC, LeffJA, BoseSK, McCordJM (2003) Synthesis and anti-inflammatory activity of a chimeric recombinant superoxide dismutase: SOD2/3. Am J Physiol Lung Cell Mol Physiol 284: L917–L925.
69. SubramaniamM, HawseJR, RajamannanNM, IngleJN, SpelsbergTC (2010) Functional role of KLF10 in multiple disease processes. Biofactors 36: 8–18.
70. AnH, ChandraV, PirainoB, BorgesL, GeczyC, et al. (2010) Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol 37: 1596–1606.
71. SinghAK, StockP, AkbariO (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 66: 155–162.
72. KellyLM, EnglmeierU, LafonI, SiewekeMH, GrafT (2000) MafB is an inducer of monocytic differentiation. EMBO J 19: 1987–1997.
73. KimH, SeedB (2010) The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat Immunol 11: 743–750.